Home » Stocks » ARPO

Aerpio Pharmaceuticals, Inc. (ARPO)

Stock Price: $1.22 USD -0.08 (-6.15%)
Updated Jan 27, 2021 2:57 PM EST - Market open
Market Cap 60.77M
Revenue (ttm) 15.00M
Net Income (ttm) -4.04M
Shares Out 42.14M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $1.22
Previous Close $1.30
Change ($) -0.08
Change (%) -6.15%
Day's Open 1.25
Day's Range 1.21 - 1.28
Day's Volume 1,453,488
52-Week Range 0.45 - 2.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 weeks ago

Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

Zacks Investment Research - 3 weeks ago

Aerpio Pharmaceuticals (ARPO) has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 3 weeks ago

CINCINNATI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio” or the “Company”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate...

Zacks Investment Research - 1 month ago

Does Aerpio Pharmaceuticals, Inc. (ARPO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Benzinga - 1 month ago

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...

Other stocks mentioned: ANPC, ARVN, SYBX, VERU
GlobeNewsWire - 1 month ago

Primary endpoint achieved with twice-daily dose group at 28 day time point versus latanoprost control group.

Zacks Investment Research - 1 month ago

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: RGEN, TCON
Seeking Alpha - 2 months ago

Aerpio Pharmaceuticals, Inc. (ARPO) Management on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Conference Call Today, November 10 , 2020 at 8:30 a.m. EST

GlobeNewsWire - 2 months ago

CINCINNATI, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat oc...

GlobeNewsWire - 2 months ago

Call Taking Place on Thursday, November 12th @ 11amET Call Taking Place on Thursday, November 12th @ 11amET

GlobeNewsWire - 3 months ago

The trial in moderate-to-severe patients is Aerpio's second clinical trial in COVID-19 patients and is funded in part by the U . S . military

GlobeNewsWire - 4 months ago

Topline Data Expected 4Q 2020 Topline Data Expected 4Q 2020

GlobeNewsWire - 4 months ago

SAN FRANCISCO and CINCINNATI, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced to...

Seeking Alpha - 5 months ago

Aerpio Pharmaceuticals' (ARPO) Management on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Conference Call Today, August 12, 2020 at 8:30 a.m. EDT

GlobeNewsWire - 5 months ago

CINCINNATI, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ...

GlobeNewsWire - 5 months ago

CINCINNATI, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (M...

Zacks Investment Research - 6 months ago

In the latest trading session, Aerpio Pharmaceuticals, Inc. (ARPO) closed at $1.26, marking a +1.61% move from the previous day.

Zacks Investment Research - 6 months ago

Is (ARPO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Aerpio Pharmaceuticals.

Zacks Investment Research - 7 months ago

Aerpio Pharmaceuticals, Inc. (ARPO) closed the most recent trading day at $1.25, moving +0.81% from the previous trading session.

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for June 19th

Other stocks mentioned: DLTH
Zacks Investment Research - 7 months ago

Is (ARPO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 7 months ago

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ARPO), today announced that, due to the public health and safety concerns related to the n...

GlobeNewsWire - 7 months ago

CINCINNATI, June 08, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ...

GlobeNewsWire - 7 months ago

SAN FRANCISCO and CINCINNATI, May 27, 2020 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced toda...

PRNewsWire - 7 months ago

SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an a...

Zacks Investment Research - 8 months ago

Aerpio Pharmaceuticals, Inc. (ARPO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 8 months ago

Aerpio Received an Immediate Payment of $15 million Aerpio Received an Immediate Payment of $15 million

Zacks Investment Research - 9 months ago

Aerpio Pharmaceuticals, Inc. (ARPO) closed at $0.72 in the latest trading session, marking a +0.61% move from the prior day.

Zacks Investment Research - 9 months ago

Is (ARPO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 9 months ago

Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Seeking Alpha - 10 months ago

Aerpio Pharmaceuticals, Inc. (ARPO) on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Our year-end roundtable rolls into 2020 with a look at small-cap investing.

Other stocks mentioned: ALX, BWEL, PFIN, STAR, TPL, WSTL
Zacks Investment Research - 1 year ago

Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 1 year ago

Aerpio Pharmaceuticals, Inc. (ARPO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Market Watch - 1 year ago

Shares of Aerpio Pharmaceuticals Inc. plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopa...

About ARPO

Aerpio Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company's lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hyp... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
ARPO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ARPO stock is "Buy." The 12-month stock price forecast is 1.75, which is an increase of 43.44% from the latest price.

Price Target
$1.75
(43.44% upside)
Analyst Consensus: Buy